MOTS-c vs. SS-31: A Simple Guide to the Research

MOTS-c and SS-31 often come up in conversations about energy and healthy aging. If the names sound like passwords you forgot, you are not alone. Let’s start with the basic idea before getting into the research.

In simple terms

Now we can take the next step: what have scientists actually found, and which parts are still unanswered?

One detail worth knowing early: Forzinity, a prescription elamipretide product, received a specific FDA accelerated approval for a rare disease called Barth syndrome, in patients weighing at least 30 kg. That is not approval of research-labeled SS-31 vials or a general anti-aging indication.^[5]

Why scientists are interested in mitochondria

Your cells need energy to do their everyday work. Mitochondria help make ATP, a molecule cells use to power that work. If food is the raw fuel, ATP is closer to the usable energy the cell can spend. Mitochondria also help cells send and respond to signals.^{[1] [3]}

That gives researchers two different questions. Could a signal linked to mitochondria change how a cell handles energy-related stress? And could a compound that interacts with mitochondrial structures affect how the energy-making process works?

MOTS-c is especially relevant to the first question. SS-31 is especially relevant to the second. Neither question is the same as asking, “Will this make a healthy person feel better?” That requires its own evidence.

What is MOTS-c?

MOTS-c is a naturally occurring peptide made of 16 amino acids. Researchers reported its discovery in a 2015 paper in Cell Metabolism.^[1]

The science detail: its instructions are encoded in mitochondrial DNA, within a region called 12S rRNA. You do not need to memorize that name. The useful point is that mitochondria carry instructions for a small signaling peptide, not just parts of the energy-making machinery.

The early research linked MOTS-c to changes in how cells handle energy, including activation of AMPK. Think of AMPK as part of a cell’s energy-management system. It helps the cell adjust how it uses energy.

That study also reported that MOTS-c treatment prevented certain forms of insulin resistance and diet-induced obesity in mice. Insulin resistance means the body responds less well to insulin, a hormone that helps control blood sugar. The results were interesting, but they did not prove that MOTS-c treats diabetes or causes weight loss in humans.^[1]

Other research has looked at MOTS-c moving into the cell nucleus, the part of a cell that holds most of its genetic instructions, during energy-related stress. It can influence gene expression, meaning which instructions the cell uses. That is why you may see it described as a stress-response signal.^[6]

For more background, visit our MOTS-c research profile. Keep one important rule in mind: the body naturally making a substance does not prove that taking extra amounts is safe or helpful.

Does the MOTS-c exercise study mean it works like exercise?

No. A widely discussed 2021 study in Nature Communications had two different parts: experiments in mice and observations in a small group of people. Keeping those parts separate changes how you read the headline.^[2]

What happened in the mice?

Researchers gave MOTS-c to young, middle-aged, and older mice. They reported improvements in certain measures of physical performance and examined changes in cells and energy use. Those findings support more research. They do not establish that the same results happen in people.^[2]

What happened in the people?

The human portion involved 10 sedentary, healthy young men exercising on a stationary bicycle. Researchers measured the men’s own MOTS-c in blood and muscle. Levels increased around exercise, with different patterns in blood and muscle.^[2]

The participants were not given MOTS-c. The researchers were observing a peptide the participants’ bodies already made. The scientific word for that is endogenous, which simply means “produced inside the body.”

See the difference? The study showed that the body’s MOTS-c responds to exercise. It did not show that injected MOTS-c improves endurance, replaces a workout, or extends human lifespan. “Exercise in a bottle” is a catchy phrase, not the finding of this human study.

What about a compound called CB4211?

You may see CB4211 mentioned alongside MOTS-c. ClinicalTrials.gov lists a completed phase 1 study of CB4211 in healthy non-obese participants and people with nonalcoholic fatty liver disease, a buildup of fat in the liver. Phase 1 is an early stage of human drug testing. The record names CB4211 as the treatment studied and has no results posted.^[7]

Do not treat a study of CB4211 as a trial of a research vial sold as MOTS-c. A related compound is not automatically the same product. The exact molecule, product formulation, participants, and results still matter.

What is SS-31, also called elamipretide?

SS-31 is a synthetic, or lab-made, peptide containing four amino-acid building blocks. Unlike MOTS-c, it is not a naturally occurring signal encoded in mitochondrial DNA.^[3]

Its research story focuses on the inner mitochondrial membrane. A membrane is a thin layer. This one is folded and helps organize the machinery involved in making ATP.

One important part of that membrane is cardiolipin, a fatty molecule. Another player is cytochrome c, a protein that carries electrons as part of the energy-making process. You do not need to remember the names to understand the main point: researchers are studying how these parts work together.^[3]

In a 2014 laboratory study, SS-31 interacted with cardiolipin and affected its relationship with cytochrome c. Researchers reported more efficient electron transport and ATP production in isolated mitochondria. “Isolated” means the mitochondria were studied outside the animal, including mitochondria taken from rat kidneys.^[3]

In simple terms: scientists saw changes in the energy-making process in a laboratory experiment. They did not show that SS-31 improves everyday energy levels in healthy adults.

That is why “studied for mitochondrial function” is fairer than “repairs everyone’s aging mitochondria.” Our SS-31 research profile provides more background.

What have SS-31 studies in people found?

Elamipretide has been studied in human clinical trials more extensively than the native MOTS-c research discussed here. But “studied in people” does not mean “proven to help everyone.” The condition being treated and the result being measured matter.

One large trial did not reach its main goals

The MMPOWER-3 trial enrolled 218 adults with genetically confirmed primary mitochondrial myopathy. That is a group of disorders affecting how mitochondria produce energy in muscle. Participants received elamipretide or a placebo, an inactive comparison treatment, for 24 weeks.^[4]

The trial was randomized and double-blind. In everyday language, people were assigned to groups by chance, and neither the participants nor the researchers knew who was receiving which treatment during the study.

The trial did not meet its primary endpoints. Endpoints are the results researchers plan to measure. Here, the main goals were improvements in six-minute walking distance and total fatigue. Elamipretide did not show a significant improvement over placebo for those main goals in the overall study group.^[4]

Researchers reported that treatment was generally well tolerated. That means its side effects were considered manageable in that study. It does not mean it was effective, risk-free, or suitable for healthy people.

This is a useful reminder: a convincing explanation of how a drug might work is not the same as a trial showing that it helped patients.

One prescription product received approval for a specific rare disease

On September 19, 2025, the FDA granted accelerated approval to Forzinity, a prescription elamipretide product, for Barth syndrome in patients weighing at least 30 kg. Barth syndrome is a rare, serious mitochondrial disease.^[5]

The approval was based on improved strength in the muscle used to straighten the knee. FDA considered that improvement reasonably likely to predict a benefit for patients.

What does “accelerated approval” mean here? It means the FDA allowed the product for this specific condition based on an early measure of likely benefit, while requiring more evidence. It required a post-approval randomized, placebo-controlled trial to confirm that the strength changes translate into benefits for patients.^[5]

That approval matters. But it does not prove that a research-labeled SS-31 vial is equivalent to Forzinity, or that elamipretide slows aging in healthy adults.

There is no contradiction between this approval and the unsuccessful MMPOWER-3 trial. They involved different medical conditions and different goals. You cannot combine them into one blanket claim that SS-31 “works” or “does not work” for every purpose.

The differences worth remembering

Where they come from: MOTS-c is a naturally occurring peptide with 16 amino acids, encoded in mitochondrial DNA. SS-31 is a lab-made peptide with four amino-acid building blocks.^{[1] [3]}

What researchers focus on: MOTS-c is studied as a signal involved in managing energy and responding to stress. SS-31 is studied for its interactions with the mitochondrial membrane and energy-making process. These are research descriptions, not promises of benefits.^{[1] [3] [6]}

What the human evidence looks like: The often-cited MOTS-c exercise study measured the body’s own peptide in a small group of men. Elamipretide has randomized clinical-trial evidence and a specific accelerated approval. Neither establishes a general anti-aging benefit for healthy people.^{[2] [4] [5]}

So which one is “better”? Better for what, and for whom? The studies discussed here do not directly compare the two for healthy aging. Picking a winner would make the research sound more settled than it is.

What should a beginner know about safety?

FDA’s compounding safety page states that it has not identified human exposure data for drug products containing MOTS-c administered by any route. In plain English, FDA has not identified human data for people receiving MOTS-c drug products. That is different from measuring MOTS-c the body naturally makes.^[8]

The agency also raises concerns about immune reactions, impurities left over from peptide production, and whether the active ingredient is fully identified and understood. An immune reaction means the body’s defense system reacts to a substance. These are reasons not to assume that “naturally occurring” means safe to administer.

For elamipretide, FDA reported that common trial side effects included mild-to-moderate reactions where the injection was given. Serious reactions had also been reported. An approved prescription medicine can still carry risks.^[5]

Research-use-only means a product is intended for research, not that it has been shown suitable for human use. A high purity percentage also does not make a research product equivalent to the prescription product studied in a trial. Our guide to reading a peptide certificate of analysis explains what a lab report can and cannot tell you.

This article does not provide dosing, injection instructions, cycling schedules, or a recommendation to combine these compounds. Two different mechanisms do not prove that a combination is safe or effective.

Four simple questions to ask about a peptide claim

1. What exactly was studied? Was it this molecule and this product, or something related?
2. Who or what was studied? A cell, an isolated mitochondrion, a mouse, a person with a rare disease, or a healthy adult?
3. What actually improved? A lab measurement, walking distance, muscle strength, and lifespan are not the same thing.
4. What is still unknown? Look for safety gaps, unsuccessful trials, and benefits that still need confirmation.

You do not need a science degree to ask those questions. They are a practical way to separate an interesting research finding from a sales pitch. Our guide to the peptide research landscape will help you build that skill.

The bottom line

MOTS-c and SS-31 both connect to how cells handle energy, but researchers study them in different ways. MOTS-c is mainly discussed as a signal. SS-31 is mainly discussed for its interactions with mitochondrial structures involved in energy production.

The research is worth understanding. It is not proof that either peptide will make a healthy person more energetic or slow their aging. Mouse results are not human treatment results. A rare-disease approval is not a general anti-aging approval. And two interesting peptides are not a proven combination.

For educational and research purposes only. Not medical advice. Research-use-only compounds are not intended for human consumption. This article is not a treatment recommendation and does not establish safety or effectiveness for personal use. Regulatory information was checked on October 22, 2026.

References

1. Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism, 2015.
2. Reynolds JC et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications, 2021.
3. Birk AV et al. Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesis. British Journal of Pharmacology, 2014.
4. Karaa A et al. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. Neurology, 2023.
5. U.S. Food and Drug Administration. FDA Grants Accelerated Approval to First Treatment for Barth Syndrome. September 19, 2025.
6. Zheng Y et al. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation. Frontiers in Endocrinology, 2023. Review.
7. ClinicalTrials.gov. NCT03998514: A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease. Trial registry, accessed October 22, 2026.
8. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. MOTS-c entry, accessed October 22, 2026.